Status:
COMPLETED
Contrast-Induced Nephropathy After Revision of the Prophylaxis Threshold
Lead Sponsor:
Maastricht University Medical Center
Conditions:
Contrast-induced Nephropathy
Eligibility:
All Genders
18+ years
Brief Summary
After administration of intravascular iodinated contrast media Contrast-Induced Nephropathy (CIN), also known as Contrast-Induced Acute Kidney Injury (CIAKI), may occur. CIN/CI-AKI is associated with ...
Eligibility Criteria
Inclusion
- referred for an elective procedure with intravascular iodinated contrast administration at Maastricht University Medical Centre
- eGFR30-44mL/min/1.73m2 OR eGFR45-59mL/min/1.73m2 + DM OR eGFR45-59mL/min/1.73m2 + \>1 risk factor (\>age \>75 years, anaemia, cardiovascular disease, prescribed NSAID or Diuretic medication) OR multiple myeloma/lymphoplasmacytic lymphoma with small chain proteinuria.
Exclusion
- eGFR\<30mL/min/1.73m2
- Dialysis/renal replacement therapy
- emergency procedure
- intensive care patient
Key Trial Info
Start Date :
July 1 2017
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
August 1 2018
Estimated Enrollment :
1372 Patients enrolled
Trial Details
Trial ID
NCT03227835
Start Date
July 1 2017
End Date
August 1 2018
Last Update
November 15 2019
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Maastricht University Medical Center
Maastricht, Zuid-Limburg, Netherlands, 6202AZ